{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:13:04Z","timestamp":1793862784649,"version":"4.6.1"},"reference-count":52,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Beckley Psytech Ltd"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>\n                      To evaluate the safety and effect on clinical outcomes of depression of Beckley Psytech Ltd (BPL)-003, an intranasal formulation of 5-methoxy-\n                      <jats:italic toggle=\"yes\">N,N<\/jats:italic>\n                      -dimethyltryptamine, in patients with moderate-to-severe major depressive disorder (MDD) with treatment-resistant depression (TRD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Twelve participants with TRD were enrolled in a 12-week, open-label, phase 2a trial. Safety of a single intranasal dose of 10\u2009mg BPL-003 was assessed through clinical evaluations, treatment-emergent adverse events (TEAEs) and Readiness for Discharge Questionnaire (RDQ). Key depression-related assessments were Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score change from baseline, percentage of responders, and participants in remission on Days 2, 8, 29, 57 and 85 post-dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All participants completed the trial; 2 females, 10 males, aged 31\u201355\u2009years. Nine (75.0%) participants had 18 treatment-related TEAEs; 8 mild, 9 moderate and 1 severe (increased blood pressure, which returned to baseline within the observation period), with nausea and nasal discomfort the most frequently reported. Ten participants were ready after their first RDQ (nominal time 90\u2009minutes post-dose). Median time from dosing to discharge readiness was 98\u2009minutes (range 95\u2013167). There was a mean decrease in MADRS total score from baseline of 12.2\u201313.0\u2009points across all timepoints between Days 2 and 85; most participants (10\/11) were responders, and 7 were in remission at \u2a7e1 post-dose timepoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12\u2009weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261420087","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:20:53Z","timestamp":1772252453000},"page":"1247-1260","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-\n                    <i>N,N<\/i>\n                    -dimethyltryptamine) in patients with treatment-resistant depression"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1705-325X","authenticated-orcid":false,"given":"Claire","family":"Roberts","sequence":"first","affiliation":[{"name":"Beckley Psytech Ltd, An AtaiBeckley Company, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Seynaeve","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd, An AtaiBeckley Company, Oxford, UK"},{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-0084","authenticated-orcid":false,"given":"Anna O.","family":"Ermakova","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd, An AtaiBeckley Company, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Dunbar","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd, An AtaiBeckley Company, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hattie","family":"Wells","sequence":"additional","affiliation":[{"name":"Beckley Psytech Ltd, An AtaiBeckley Company, Oxford, UK"},{"name":"Hammersmith Medicines Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeep","family":"Puri","sequence":"additional","affiliation":[{"name":"Hammersmith Medicines Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bird","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4647-8088","authenticated-orcid":false,"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College, London, UK"},{"name":"The South London and Maudsley NHS Foundation Trust, Beckenham, Kent, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"APA (2022) Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. APA. Available at: https:\/\/psychiatryonline.org\/doi\/abs\/10.1176\/appi.books.9780890425596."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.05.001"},{"issue":"7","key":"e_1_3_3_4_1","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 4(7): 28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.01.002"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00102.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2018.1545024"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Dunbar F Seynaeve M Ermakova A et al. (2025) Rapid sustained and meaningful antidepressant effect of intranasal BPL-003 (5-methoxy-N N-dimethyltryptamine) in treatment-resistant patients.","DOI":"10.1016\/j.biopsych.2025.02.418"},{"key":"e_1_3_3_11_1","unstructured":"EMA (2019) European Medicines Agency Science Medicines Health Spravato esketamine. EMA. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/spravato (accessed 15 April 2025)."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211050543"},{"key":"e_1_3_3_13_1","unstructured":"FDA (2019) FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression; Available only at a Certified Doctor\u2019s Office or Clinic. FDA. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified (accessed 12 February 2025)."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"key":"e_1_3_3_17_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.01.017"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2015.17.2\/dionescu"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02113-1"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2190\/T8EM-C8YH-373N-1UWD"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15020161"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00035"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.004"},{"key":"e_1_3_3_26_1","article-title":"Treatment resistant depression: What are the options?","volume":"363","author":"McLachlan G","year":"2018","unstructured":"McLachlan G (2018) Treatment resistant depression: What are the options? Bmj 363: k5354.","journal-title":"Bmj"},{"key":"e_1_3_3_27_1","unstructured":"MHRA (2021) Spravato Summary of Product Characteristics. Available at: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/dacade93a18c2d99831bf6a95a561c1922dca974 (accessed 25 April 2025)."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-025-00608-2"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.03.010"},{"key":"e_1_3_3_31_1","unstructured":"NIH (2021) Major Depression. NIH. Available at: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression (accessed 12 February 2025)."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2113692"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718001356"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230890"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009019"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1133414"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104765"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241246857"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.70088"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920010794233495"},{"key":"e_1_3_3_44_1","volume-title":"The Developing Mind: Toward a Neurobiology of Interpersonal Experience","author":"Siegel DJ","year":"1999","unstructured":"Siegel DJ (1999) The Developing Mind: Toward a Neurobiology of Interpersonal Experience. Guilford Press."},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.1.99"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.148.5.599"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13386"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05236-w"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf0435"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02477-4"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.01.142"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774512465064"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261420087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261420087","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261420087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:16:45Z","timestamp":1785734205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261420087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/02698811261420087"],"URL":"https:\/\/doi.org\/10.1177\/02698811261420087","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}